

In Silico Evaluation of the Physicochemical, Pharmacokinetics, and Toxicity Profiles of Sesquiterpene Lactones of South African Leaf (*Vernonia amygdalina* Delile)

by Nerdy N, Linda Margata,linta Meliala ,jhan S. P Bunga M. Sembiring,
Selamat Ginting, Tedy K. Bakri

Submission date: 04-Nov-2021 07:03AM (UTC+0700)

Submission ID: 1692434184

File name: manuscript_1929_21-TJNPR-2021-M372_Galley_Proof_C.pdf (262.24K)

Word count: 5185

Character count: 28554

**In Silico Evaluation of the Physicochemical, Pharmacokinetics, and Toxicity Profiles of Sesquiterpene Lactones of South African Leaf (*Vernonia amygdalina* Delile)**Nerdy Nerdy^{1*}, Linda Margata¹, Linta Meliala¹, Jhan S. Purba¹, Bunga M. Sembiring², Selamat Ginting², Tedy K. Bakri³¹Department of Pharmacy, Faculty of Pharmacy, Institut Kesehatan Deli Husada Deli Tua, Deli Tua Timur, Deli Tua, Deli Serdang, Sumatera Utara, Indonesia²Department of Public Health, Faculty of Public Health, Institut Kesehatan Deli Husada Deli Tua, Deli Tua Timur, Deli Tua, Deli Serdang, Sumatera Utara, Indonesia³Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Syiah Kuala, Kopelma Darussalam, Syiah Kuala, Banda Aceh, Aceh, Indonesia

ARTICLE INFO

Article history:

Received September 2021

Revised 06 October 2021

Accepted 21 October 2021

Published online 02 November 2021

Copyright: © 2021 Nerdy *et al.* This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

40

Cancer is a disease caused by malignant cell growth. Chemotherapeutic agents are still the primary option for cancer treatment. Various efforts to develop new treatment methods are needed for more effective cancer therapy. Cyclophosphamide is one of the essential agents used for treating cancers. The sesquiterpene lactone compounds in *Vernonia amygdalina* Delile, South African leaf contribute to its anticancer pharmacological effects in different cancers. This study aims to determine the pharmacokinetics and toxicity profiles of various sesquiterpene lactone compounds in the South African leaf. This research was initiated by a search for the physicochemical properties and Canonical Simplified Molecular Input Line Entry System (SMILES) code of each compound with the assistance of PubChem, followed by computational processing with the aid of the pKCSM and ProTox-II tools. This study involves a comparative analysis of the compounds' physicochemical properties, pharmacokinetics, toxicity profile and cyclophosphamide as the standard anticancer drug. The results showed that the physicochemical properties of the sesquiterpene lactone compounds in *Vernonia amygdalina* leaf had met Lipinski's rule of five conditions. The pharmacokinetics and toxicity profiles were similar or better than cyclophosphamide. Hydroxyvernolide has the best physicochemical, pharmacokinetics, and toxicity profile of the sesquiterpene lactones of the South African *Vernonia amygdalina* and cyclophosphamide.

Keywords: *Vernonia amygdalina* Delile, Sesquiterpene lactone, *In silico*, Physicochemical, Pharmacokinetics, Toxicity.

Introduction

Pharmacokinetics is the study of the entire process experienced by drug molecules from the time it enters the body until the drug is excreted from the body. The drug action processes in pharmacokinetics are sequentially absorption, distribution, metabolism, and excretion, which affects the half-life ($T_{1/2}$), peak time (T_{max}), the onset of action, and duration of action.¹ Toxicity is the ability of a material to have a toxic or poisonous effect for a certain period due to chemical, physiological interactions in the body. Toxicity testing of material is specific or alternative to determine risk factors.²

The process of introducing new drugs to the market is very complex, including preclinical trials and clinical trials to prove safety, efficacy, and quality.³ The safety of a developed drug compound must be verified by its low toxicity during preclinical and clinical trials.⁴ Scientific and economic pressures to minimize chemical and biological experiments and quickly and precisely screen new compounds with better pharmacokinetic and toxicity profiles have led

to accelerated processes and developments in computational chemical engineering in the pharmaceutical industry.⁵

The South Africa Leaf (*Vernonia amygdalina* Delile) is a plant from the Asteraceae family that has its origin in Africa, including Zimbabwe and Nigeria. It grows best in tropical climates and can be grown wild or planted. *Vernonia amygdalina* leaf has various pharmacological effects due to its numerous phytochemical constituents, including sesquiterpenes, triterpenes, flavonoids, alkaloids, saponins, tannins, and glycosides.⁶ The content of sesquiterpene lactone compounds contained in the leaf of the South African Leaf, *Vernonia amygdalina*, has been shown to contribute to its anticancer activity against various cancers, namely lung cancer, colorectal cancer, cervical cancer, and breast cancer.^{7,8} The sesquiterpene lactone compounds present in *Vernonia amygdalina* Leaf are vernodalol, vernodalin, vernolepin, vernomydin, vernolide, hydroxyvernolide.⁹

Cancer is excessive cell proliferation, generally embryonic, which invades and destroys the surrounding tissue. Cancer treatment with chemotherapeutic agents is still the primary option for most cancer patients.¹⁰ However, the existence of multiple drug resistance mechanisms results in reduced efficacy of chemotherapy drugs.¹¹ Various efforts to develop new treatment methods are needed for more effective cancer therapy. One of them is cyclophosphamide.¹² Alternative medicines, such as medicinal plants used to treat degenerative diseases, can reduce side effects.¹³

An excellent pharmaceutical compound is not enough to be efficacious but must also have a good pharmacokinetics and safety profile. *In silico* Physicochemical, pharmacokinetic, and toxicity analysis of the sesquiterpene lactone compounds of the South Africa Leaf have not been reported previously. This study aims to determine

*Corresponding author. E mail: nerdy190690@gmail.com
Tel: +628126300888

Citation: Nerdy N, Margata L, Meliala L, Purba MS, Sembiring BM, Ginting S, Bakri TK. *In Silico* Evaluation of the Physicochemical, Pharmacokinetics, and Toxicity Profiles of Sesquiterpene Lactones of South African Leaf (*Vernonia amygdalina* Delile). Trop J Nat Prod Res, 2021; 5(10):1835-1840. doi.org/10.26538/tjnpr/v5i10.21

43 Tropical Journal of Natural Product Research Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria.

the pharmacokinetics and toxicity profile of various sesquiterpene lactone compounds present in the South Africa Leaf.

Materials and Methods

Hardware

The hardware used in this study is a laptop with a Processor specification with the type Advanced Micro Devices, Inc. (AMD) Ryzen 7 - 3700U with Radeon Vega Mobile Gfx 2.30 GHz, Random Access Memory (RAM) with a capacity of 8 GB, and Read-Only Memory (ROM) capacity of 512 GB.

Software

The software used in this study is PubChem (<https://pubchem.ncbi.nlm.nih.gov>) for molecular structure of compounds, pkCSM (<http://biosig.unimelb.edu.au/pkcsml/prediction>) and ProTox-II (https://tox-new.charite.de/protox_II/index.php?site=compound_input) for pharmacokinetic analysis and toxicity analysis.

Methods

Prediction of the physicochemical, pharmacokinetic, and toxicity properties of the South Africa sesquiterpene lactone compounds (vernodalol, vernodalin, vernolepin, vernomygdin, vernolide, hydroxyvernolide) as test compounds and cyclophosphamide as standard oral chemotherapy agents with a search for the physicochemical properties and Canonical Simplified Molecular Input Line Entry System (SMILES) code with the assistance of PubChem website, followed by computational processing using pkCSM and ProTox-II websites. The process ends with an analysis of the computational data generated on the compounds' physicochemical, pharmacokinetic, and toxicity properties compared to cyclophosphamide as the standard anticancer drug.

Results and Discussion

The structure of the compound was obtained from PubChem in the Simplified Molecular Input Line Entry System (SMILES) format for physicochemical, pharmacokinetic, and toxicity analysis using pkCSM and ProTox-II (Figure 1).




Figure 1: Structure of the South Africa Leaf Sesquiterpene Lactone Compounds and Cyclophosphamide used for Pharmacokinetic and Toxicity Analysis

*a: vernodalol; b: vernodalin; c: vernolepin; d: vernomygdin; e: vernolide; f: hydroxyvernolide; g: cyclophosphamide

Preliminary analysis of the physicochemical properties was carried out to assess the fulfillment of Lipinski's rule of five of the compounds to be analyzed. The physicochemical properties analyzed include hydrogen bond donors, hydrogen bond acceptors, molecular mass, and partition coefficient obtained from PubChem, as shown in Table 1. Lipinski's rule of five requires that a drug lead have a molecular mass of less than 500 Daltons, a partition coefficient of not more than five, five hydrogen bond donors, and more than 10 hydrogen bond acceptors. The above analysis is known as Lipinski's rule of five because all values are multiples of the number five. Active drugs with oral administration must comply with Lipinski's rule of five with no more than one violation.¹⁴ The results showed that both South Africa Leaf sesquiterpene lactone compounds and cyclophosphamide met Lipinski's rule. Both drug candidates possess good oral administration and intestinal absorption. The number of rotating bonds is a parameter of the flexibility of a compound, widely used in the process of discovering new drugs or drug candidates. A compound is declared to have good permeability and bioavailability if it has no fewer than 15 rotating bonds.¹⁵ The results showed that both South Africa Leaf sesquiterpene lactone compounds and cyclophosphamide had a range of 1–8 rotating bonds, meaning that all of them have good flexibility, permeability, and bioavailability.

Pharmacokinetic and toxicity analysis was carried out by pkCSM using several parameters: for absorption (intestinal absorption and skin permeability), for distribution (distribution volume, fraction unbound, blood-brain barrier permeability), and central nervous system permeability), for metabolism (CYP2D6 substrate CYP3A4 substrate CYP2D6 inhibitor, and CYP3A4 inhibitor), and excretion (total clearance and renal organic cation transporter substrate). Toxicity parameters investigated include Ames toxicity test, hERG I inhibitor, hERG II inhibitor, median lethal dose (LD50), lowest observed adverse effect level (LOAEL), and hepatotoxicity. Other parameters, including hepatotoxicity, carcinogenicity, and mutagenicity, were analyzed with ProTox-II (see Table 2).

Compounds with more than 70% absorption are declared as drugs with good absorption, while those with less than 30% are reported as poorly absorbed drugs. The intestine is the leading site for absorption of the main drug in oral drug administration.¹⁶ The results showed that the predicted intestinal absorption values for both South Africa Leaf sesquiterpene lactone compounds and cyclophosphamide were in the range of 75% to 100%.

The predicted intestinal absorption values indicate that all of these compounds have good absorption.

A compound is declared to have good skin permeability with a value of less than -2.5. The results showed that the predicted skin permeability value (log Kp) for compounds was in the range of -3.867 to -2.908, while the predicted skin permeability value for cyclophosphamide was -2.281. This comparison shows that South Africa Leaf compounds have better skin permeability than cyclophosphamide.

The volume of distribution is the theoretical volume of the total dose of a drug required to be evenly distributed to give the same concentration in the blood plasma. A high volume of distribution indicates that the drug is distributed at high concentrations in tissues and low concentrations in plasma.¹⁷ A compound is categorized as having a low volume of distribution if the logVD value is less than -0.15 and having a high distribution volume if the logVD value is less than 0.45.¹⁸ The results showed that the predicted logVD value of the compounds ranged from -0.236 to 0.198 (vernodalol being the least and hydroxyvernolide the highest), while the predicted logVD value for cyclophosphamide was -0.198. The predicted unbound fraction for vernodalol and vernodalol did not show a significant difference compared to cyclophosphamide, which means both have a similar distribution profile.

The concentration of unbound drug in systemic circulation determines the concentration of the active drug that could exert a pharmacological effect.¹⁹ The results showed that the predicted unbound fraction for the test compounds was ranged from 0.404 to 0.551 (vernomygdin was the least while hydroxyvernolide the highest), while the predicted unbound fraction for cyclophosphamide was 0.586. The predicted unbound fraction for hydroxyvernolide was not significantly different from cyclophosphamide, suggesting a similar pharmacological effect with standard anticancer drug cyclophosphamide.

The ability of a drug to pass through the blood-brain barrier is an essential parameter of the toxicity of a drug or its efficacy in the brain.²⁰ This quality or permeability is expressed as logBB value, which is the logarithmic ratio of the drug concentration in the brain to the drug concentration in plasma. The greater the logBB value, the greater the drug penetrability into the brain.²¹ At a logBB value of 0.3, the compound can easily penetrate the blood-brain barrier and moderate penetration at logBB < -1.0.²² The results showed that the logBB values for the compounds and cyclophosphamide were in the range of -0.684 and 0.195. The overall predicted logBB value is in the range of -1.0 and 0.3, suggesting that the test compounds have moderate BBB penetration.

In addition to the logBB value, there is another gold standard for measuring permeability in the brain, namely the logPS value. The logPS value is considered a more informative data point.²³ The drug permeability into the brain and the central nervous system is expressed as logPS value. It is the logarithmic ratio of permeability surface-area product to the central nervous system. The higher the logPS value, the higher the drug penetration ability.²⁴ The compound is considered to easily penetrate the central nervous system if the logPS value is

greater than -2 and less likely to penetrate the blood-brain barrier if logPS is less than -3.²⁵ The results showed that the logPS values for both the test compounds and cyclophosphamide were in the range of -3.179 and -2.975. The overall predicted logPS value for the test compounds is less than -3 (except vernolepin), indicating that they possess moderate penetration into the central nervous system.

Metabolic enzymes in the liver that act as biomarkers to determine the effect of drug response are Cytochrome P450 (CYP450) enzymes, which oxidatively metabolize endogenous substrates and foreign compounds.¹⁹ There are 10 types of Cytochrome P450 (CYP450) enzymes in the human liver, CYP1, CYP2 and CYP3 isoenzyme families involved in drug metabolism. The most dominant types of Cytochrome P450 (CYP450) enzymes found in humans are CYP2D6 (20.0%) and CYP3A4 (30.2%).²⁶

The Cytochrome P450 enzymes metabolize drugs (substrates) into different metabolites, which can easily be excreted.²⁷ The results predict that the test compounds are not CYP2D6 and CYP3A4 substrates, except vernodalol, vernomygdin, and vernolide. Thus, they predicted not to be rapidly metabolized or quickly excreted. Inhibition of Cytochrome P450 (CYP450) enzymes can lead to clinically adverse drug interactions.²⁸ If a drug is not a substrate in the metabolic process by the cytochrome P450 enzyme, the process of drug washout from the body becomes slower, and the dose of the drug can be minimized.²⁹ The results predict that the test compounds do not inhibit CYP2D6 enzymes and CYP3A4 enzymes. Hence these compounds may not cause clinically adverse drug interactions.

The total clearance (TC) parameter is a combination of hepatic clearance (metabolism in the liver and bile) and renal clearance (excretion through the kidneys). TC is related to bioavailability, and it is essential to determine the dose level in achieving steady-state concentrations.³⁰ The results showed that the predicted total clearance value (log mL per minute per kg body weight) for the test compounds was in the range of 0.665 to 1.267, while the predicted total clearance value for cyclophosphamide was 0.628. The predicted TC value shows that the test compounds have faster excretion rates than cyclophosphamide.

The kidney is an organic cation transporter (OCT). This transporter plays a vital role in the disposition and excretion of drug compounds. The OCT plays a role in drug entry by bridging the transport of several cation compounds from basolateral to apical renal tubular cells.³¹ The isoform organic cation transporter 2 (OCT2) is primarily responsible for drug accumulation in the kidney. The isoform 1 (OCT1) is majorly accountable for drug accumulation in the liver.³² Drug compounds which are organic cation transporter substrates in tissues, can cause drug toxicity in certain organs. The prediction results indicate that the test compounds and cyclophosphamide are not substrates for organic cation transporters (OCT), so they do not cause organ toxicity.

A mutagenic test is a primary screening test to determine the possibility of mutagenicity of a drug compound. The Ames test is one of the methods used to detect the mutagenic effect of a drug substance based on a reverse mutation system.

Table 1: Results of physicochemical properties of South Africa Leaf (*Vernonia amygdalina* Delile) Sesquiterpene Lactone Compounds and Cyclophosphamide

Compounds	Molecular Mass	Partition Coefficient	Hydrogen Bond Donors	Hydrogen Bond Acceptors	Rotatable Bonds
Vernodalol	392.4	1.2	2	8	8
Vernodalol	360.4	1.6	1	7	5
Vernolepin	276.3	1.3	1	5	1
Vernomygdin	364.4	1.0	1	7	3
Vernolide	362.4	0.9	1	7	3
Hydroxyvernolide	378.4	-0.3	2	8	4
Cyclophosphamide	261.1	0.6	1	4	5

Based on several studies, mutagenic substances may be carcinogenic.³³ Mutations are permanent changes in genes that may be responsible for many genetic disorders that result in certain cancers or syndromes.³⁴ Cancer is a disease characterized by malignant cells/tissues that grow quickly and uncontrollably and spread to other places in the patient's body.³⁵ From this study, it is predicted that vernolide and hydroxyvernolide have negative Ames toxicity. Additionally, vernodalol, vernodalin, and vernolepin were negative for mutagenicity and carcinogenicity. However, vernomygdin and cyclophosphamide were positive in the measure of Ames toxicity, mutagenicity, and carcinogenicity.

Cardiotoxicity is used for heart damage and dysfunction resulting from exposure to toxic chemical compounds or drug compounds.³⁶ The cardiotoxicity of the drug arises due to inhibition of the human Ether-a-go-go related gene (hERG) that causes blockage of potassium ion channels.³⁸ The blockage causes a prolongation of the QT interval of the heart, a severe life-threatening cardiac side effect.³⁷ Hepatotoxicity is injury or damage to the liver caused by chemicals or drugs. Hepatotoxicity can be caused by the use of an inappropriate type or dose of medicine.³⁸ The results of the prediction of cardiotoxicity showed that both the test compounds and cyclophosphamide do not inhibit human Ether-a-go-go related gene (hERG). The lowest observed adverse effect level (LOAEL) is the lowest concentration of a substance or drug that can cause adverse effects. The lower the value of LOAEL, the more toxic the compound.³⁹ The prediction results for the LOAEL showed that the dose range for the compounds was 1.107 mg per kg body weight to 2.087 mg per kg body weight, while

cyclophosphamide had LOAEL of 0.518 mg per kg body weight. Overall, the LOAEL obtained for the test compounds were higher than cyclophosphamide, indicating that the compounds were less toxic than cyclophosphamide. All the South Africa Leaf sesquiterpene lactone compounds are predicted not to cause skin sensitization, while cyclophosphamide is predicted to cause skin sensitization. Thus, South Africa Leaf sesquiterpene lactone compounds may be safer for the skin.

The median lethal dose (LD50) of a substance or drug is the amount that causes mortality in 50% of test animals in an experiment. The lower the LD50 value, the lower the safety of the compound.⁴⁰ Prediction results for the LD50 indicate that the dose range for the compounds was 556.469 to 1,494.301 mg per kg body weight per day. Cyclophosphamide showed LD50 of 931.865 mg per kg body weight per day. Overall, the LD50 predicted for these compounds was higher than cyclophosphamide, except vernodalin and vernolepin. This value indicates that the South Africa Leaf sesquiterpene lactone compounds are safer than cyclophosphamide.

South Africa Leaf sesquiterpene lactone compounds have lower toxicity and are safer than cyclophosphamide. Cyclophosphamide showed higher Ames test toxicity, mutagenicity, carcinogenicity, and hepatotoxicity compared to the test compounds. The sesquiterpene lactone compounds in South Africa Leaf occur in small amounts. These compounds are known to exert additive or synergistic pharmacological effects. Botanicals (natural products) are considered to be safer with low toxicity compared to synthetic agents.⁴¹

Table 2: Pharmacokinetic and Toxicity Results of South Africa Leaf (*Vernonia amygdalina* Delile) Sesquiterpene Lactone Compounds and Cyclophosphamide

Property	Del Name	A	B	C	D	E	F	G
	Intestinal							
Absorption	Absorption (human)(%)	75.395	96.144	75.645	100.000	100.000	96.455	91.508
	Absorbed							
	Skin							
Absorption	Permeability(log)	-3.447	-3.222	-3.867	-3.118	-3.086	-2.908	-2.281
	VDss (human)(log)							
Distribution	L/kg	-0.197	-0.236	0.017	0.107	0.156	0.198	-0.198
	Fraction Unbound (human)(Fu)							
Distribution	Permeability(log)	-0.480	-0.684	-0.193	-0.571	-0.566	-0.423	0.195
	BBB							
	CNS							
Distribution	Permeability(log)	-3.049	-3.061	-2.975	-3.072	-3.092	-3.179	-3.055
	PS							
Metabolism	CYP2D6 Substrate(Yes/No)	No	No	No	No	No	No	No
Metabolism	CYP3A4 Substrate(Yes/No)	No	Yes	No	Yes	Yes	No	No
Metabolism	CYP2D6 Inhibitor(Yes/No)	No	No	No	No	No	No	No
Metabolism	CYP3A4 Inhibitor(Yes/No)	No	No	No	No	No	No	No
Excretion	Total	0.747	0.725	0.665	1.053	1.184	1.267	0.628

	Clearance(log ml/min/kg)							
Excretion	Renal OCT Substrate(Yes/No)	No	No	No	No	No	No	No
Toxicity	Ames Toxicity(Yes/No)	Yes	Yes	Yes	Yes	No	No	Yes
Toxicity	hERG I inhibitor(Yes/No)	No	No	No	No	No	No	No
Toxicity	hERG II inhibitor(Yes/No)	No	No	No	No	No	No	No
Toxicity	Oral Rat Acute Toxicity (LD50)(mol/kg)	2.388 937.051	2.285 823.514	2.014 556.468	3.413 1243.697	3.467 1256.440	3.949 1494.301	3.569 931.865
Toxicity	Oral Rat Chronic Toxicity (LOAEL)(log mg/kg_bw/day)	1.971	1.768	1.405	1.134	1.107	2.087	0.518
Toxicity	Skin Sensitisation(Yes/ No)	No	No	No	No	No	No	Yes
Toxicity	Hepatotoxicity(Yes/ No)	No	No	No	No	No	No	No
Toxicity	Carcinogenicity(Yes/ No)	No	No	No	Yes	No	No	Yes
Toxicity	Mutagenicity(Yes/ No)	No	No	No	Yes	Yes	Yes	Yes

*A: Vernodalol; B: Vernodalin; C: Vernolepin; D: Vernomygdin; E: Vernolide; F: Hydroxyvernolide; G: Cyclophosphamide

Conclusion

In silico physicochemical, pharmacokinetic, and toxicity profiles analysis of the South Africa Leaf sesquiterpene lactone compounds showed better profiles than the standard anticancer agent, cyclophosphamide. In conclusion, hydroxyvernolide has the best physicochemical, pharmacokinetic, and toxicity profiles of the compounds investigated.

Conflict of Interest

The authors declare no conflict of interest in this study.

Authors' Declaration

The authors hereby declare that the work presented in this article are original and that any liability for claims relating to the content of this article will be borne by them

Acknowledgements

The author would like to thank the Deli Husada Deli Tua Health Institute for the support of facilities in conducting this research.

References

1. Tjandrawinata RR, Setiawati A, Nofiarny D, Susanto LW, Setiawati E. Pharmacokinetic Equivalence Study of Nonsteroidal Anti-Inflammatory Drug Etoricoxib. *Clin Pharmacol*. 2018; 10(4):43-51.
2. McCarty LS, Borgert CJ, Burgoon LD. Evaluation of the Inherent Toxicity Concept in Environmental Toxicology and Risk Assessment. *Environ Toxicol Chem*. 2020; 39(12):2351-2360.
3. Mohs RC and Greig NH. Drug Discovery and Development: Role of Basic Biological Research. *Alzheimer's Dement*. 2017; 3(11):651-657.
4. Andrade EL, Bento AF, Cavalli J, Oliveira SK, Schwanke RC, Siqueira JM, Freitas CS, Marcon R, Calixto JB. Non-Clinical Studies in the Process of New Drug Development - Part II: Good Laboratory Practice, Metabolism, Pharmacokinetics, Safety and Dose Translation to Clinical Studies. *Braz J Med Biol Res*. 2016; 49(12):e5646.
5. Daley S and Cordell GA. Natural Products, the Fourth Industrial Revolution, and the Quintuple Helix. *Nat ProdCommun*. 2021; 16(3): 1-31.
6. Howard C, Johnson W, Pervin S, Izevbigie E. Recent perspectives on the anticancer properties of aqueous extracts of Nigerian *Vernonia amygdalina*. *Botanics*. 2015; 5(11): 65-76.

7. Joseph J, Lim V, Rahman HS, Othman HH, Samad NA. Anti-Cancer Effects of *Vernonia amygdalina*: A Systematic Review. Trop J Pharm Res. 2020; 19(8):1775-1784.
8. Hasibuan PAZ, Harahap U, Sitorus P, Satria D. The Anticancer Activities of *Vernonia amygdalina* Delile, Leaves on 4T1 Breast Cancer Cells through Phosphoinositide 3-Kinase (PI3K) Pathway. Heliyon. 2020; 6(7):e04449.
9. Abay SM, Lucantoni L, Dahiya N, Dori G, Dembo EG, Esposito F, Lupidi G, Ogboi S, Ouédraogo RK, Sinisi A, Tagliatalata-Scafati O, Yerbanga RS, Bramucci M, Quassinti L, Ouédraogo JB, Christophides G and Habluetzel A. *Plasmodium* Transmission Blocking Activities of *Vernonia amygdalina* Extracts and Isolated Compounds. Malar J. 2015; 14(7):288.
10. Tohme S, Simmons RL, Tsung A. Surgery for Cancer: A Trigger for Metastases. Cancer Res. 2017; 77(7):1548-1552.
11. Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci. 2020; 21(5):3233.
12. Falzone L, Salomone S, Libra M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 2018; 9(11):1300.
13. Prasansuklab A, Brimson JM, Tencomnao T. Potential Thai Medicinal Plants for Neurodegenerative Diseases: A Review Focusing on the Anti-Glutamate Toxicity Effect. J Trad Compl Med. 2020; 10(3):301-308.
14. Benet LZ, Hosey CM, Ursu O, Oprea TI. BDDCS, the Rule of 5 and Drugability. Adv Drug Deliv Rev. 2016; 101(6):89-98.
15. Maliehe TS, Tsiilo PH, Shandu JS. Computational Evaluation of ADMET Properties and Bioactive Score of Compounds from *Encephalartosferox*. Pharmacogn J. 2020; 12(6):1357-1362.
16. Xu R, Yuan Y, Qi J, Zhou J, Guo X, Zhang J, Zhan R. Elucidation of the Intestinal Absorption Mechanism of Loganin in the Human Intestinal Caco-2 Cell Model. Evid-Based Compl Altern Med. 2018; 2018 (6):8340563.
17. Koziolok M, Alcaro S, Augustijns P, Basit AW, Grimm M, Hens B, Hoad CL, Jedamzik P, Madla CM, Maliepaard M, Marciani L, Maruca A, Parrott N, Pávek P, Porter CJH, Reppas C, van Riet-Nales D, Rubbens J, Statelova M, Trevaskis NL, Valentovak K, Vertzoni M, epo DV, Corsetti M. The Mechanisms of Pharmacokinetic Food-Drug Interactions - A Perspective from the UNGAP Group. Eur J Pharm Sci. 2019; 134 (15):31-59.
18. Hardjono S, Widiandani T, Purwanto BT, Nasyanka AL. Molecular Docking of N-benzoyl-N'-(4-fluorophenyl) thiourea Derivatives as Anticancer Drug Candidate and Their ADMET Prediction. Res J Pharm Technol. 2019; 12 (5):2160-2166.
19. Gonzalez D, Schmidt S, Derendorf H. Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents. Clin Microbiol Rev. 2013; 26 (2):274-288.
20. Wala K, Szlasa W, Saczko J, Rudno-Rudzinska, J, Kulbacka J. Modulation of Blood-Brain Barrier Permeability by Activating Adenosine A2 Receptors in Oncological Treatment. Biomol. 2021; 11(4):633.
21. Gao Z, Chen Y, Cai X, Xu R. Predict Drug Permeability to Blood-Brain-Barrier from Clinical Phenotypes: Drug Side Effects and Drug Indications. Bioinform. 2017; 33 (6):901-908.
22. Krihariyani D, Wasito EB, Isaeni I, Siswodihardjo S, Yuniarti WM, Kumiawan E. *In Silico* Study on Antibacterial Activity and Brazilian ADME of Sappan Wood (*Caesalpinia Sappan* L.) Against *Escherichia coli* (Strain K12). Sys Rev Pharm. 2020; 11(10): 290-296.
23. Carpenter TS, Kirshner DA, Lau EY, Wong SE, Nilmeier JP, Lightstone FC. A Method to Predict Blood-Brain Barrier Permeability of Drug-Like Compounds Using Molecular Dynamics Simulations. Biophys J. 2014; 107(8):630-641.
24. Stepnik K and Kukula-Koch W. *In Silico* Studies on Triterpenoid Saponins Permeation through the Blood-Brain Barrier Combined with Postmortem Research on the Brain Tissues of Mice Affected by Astragaloside IV Administration. Int J Mol Sci. 2020; 21(4): 2534.
25. Hadni H and Elhallaoui M. 3D-QSAR, Docking and ADMET Properties of Aurone Analogues as Antimalarial Agents. Heliyon. 2020; 6(3): e03580.
26. Zanger UM and Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138(1):103-141.
27. Chen J, Jiang S, Wang J, Renukuntla J, Sirimulla S, Chen J. A Comprehensive Review of Cytochrome P450 2E1 for Xenobiotic Metabolism. Drug Metab Rev. 2019; 51(2):1-60.
28. Deodhar M, Rihani SBA, Arwood MJ, Darakjian L, Dow P, Turgeon J, Michaud V. Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceut. 2020; 12(1):846.
29. Zhang A and Tang W. Drug Metabolism in Drug Discovery and Development. Acta Pharm Sin B. 2018; 8(5):721-732.
30. Choi GW, Lee YB, Cho HY. Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling. Pharmaceut. 2019; 11(4): 168.
31. Yin J and Wang J. Renal Drug Transporters and Their Significance in Drug-Drug Interactions. Acta Pharm Sin B. 2016; 6(5):363-373.
32. Zhou S, Zeng S, Shu Y. Drug-Drug Interactions at Organic Cation Transporter 1. Front Pharmacol. 2021; 12(2):628705.
33. Smith CJ and Perfetti TA. Statistical Treatment of Cytotoxicity in Ames Bacterial Reverse Mutation Assays Can Provide Additional Structure-Activity Relationship Information. Toxicol Res Appl. 2020; 4(3):1-5.
34. Honma M. An Assessment of Mutagenicity of Chemical Substances by (Quantitative) Structure-Activity Relationship. Gene Environ. 2020. 42(7): 23.
35. dos Santos AF, de Almeida DRQ, Terra LF, Baptista MS, Labriola L. Photodynamic Therapy in Cancer Treatment - An Update Review. J Cancer Metastasis Treat. 2019; 5(3):25.
36. Trapani D, Zagami P, Nicolo E, Pravettoni G, Curigliano G. Management of Cardiac Toxicity Induced by Chemotherapy. J Clin Med. 2020; 9(9): 2885.
37. Lee HM, Yu MS, Kazmi SR, Oh SY, Rhee KH, Bae MA, Lee BH, Shin DS, Oh KS, Ceong H, Lee D, Na D. Computational Determination of hERG- Related Cardiotoxicity of Drug Candidates. Bioinfo. 2019; 20(10):250.
38. Gerussi A, Natalini A, Antonangeli F, Mancuso C, Agostinnetto E, Barisani D, Rosa FD, Andrade R, Invernizzi P. Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. Int J Mol Sci. 2021; 22(4):4557.
39. Gadaleta D, Marzo M, Toropov A, Toropova A, Lavado GJ, Escher SE, Dorne JLCM, Benfenati E. Integrated *In Silico* Models for the Prediction of No-Observed-(Adverse)-Effect Levels and Lowest-Observed-(Adverse)-Effect Levels in Rats for Sub-chronic Repeated-Dose Toxicity. Chem Res Toxicol. 2021; 34(2):247-257.
40. Morris-Schaffer K and McCoy MJ. A Review of the LD50 and Its Current Role in Hazard Communication. ACS Chem Health Saf. 2021; 28(1):25-33.
41. Batiha GES, Beshbishy AM, Ikram M, Mulla ZS, El-Hack MEA, Taha AE, Algammal AM, Elewa YHA. The Pharmacological Activity, Biochemical Properties, and Pharmacokinetics of the Major Natural Polyphenolic Flavonoid: Quercetin. Foods. 2020; 9(3):374.

In Silico Evaluation of the Physicochemical, Pharmacokinetics, and Toxicity Profiles of Sesquiterpene Lactones of South African Leaf (*Vernonia amygdalina* Delile)

ORIGINALITY REPORT

17%

SIMILARITY INDEX

11%

INTERNET SOURCES

13%

PUBLICATIONS

7%

STUDENT PAPERS

PRIMARY SOURCES

- 1 Ruth Johnson, Kathryn S. Burch, Kangcheng Hou, Mario Paciuc, Bogdan Pasaniuc, Sriram Sankararaman. "Estimation of regional polygenicity from GWAS provides insights into the genetic architecture of complex traits", *PLOS Computational Biology*, 2021
Publication 1%
- 2 www.jurnal.unsyiah.ac.id
Internet Source 1%
- 3 Arun Parashar, Arpit Shukla, Ankush Sharma, Tapan Behl, Dweipayan Goswami, Vineet Mehta. " Reckoning γ -Glutamyl-S-allylcysteine as a potential main protease (m) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation ", *Drug Development and Industrial Pharmacy*, 2021
Publication 1%
- 4 Submitted to University of Nottingham
Student Paper

1 %

5

adekunle rowaiye, Olukemi Onuh, Joy Awulika Oladimeji-Salami, Doofan Bur et al. "In Silico Identification of the Potential Natural Inhibitors of SARS-CoV-2 Guanine-N7 Methyltransferase.", American Chemical Society (ACS), 2020

Publication

1 %

6

ia801702.us.archive.org

Internet Source

1 %

7

"Molecular docking of various bioactive compounds from essential oil of *Trachyaspermum ammi* against the fungal enzyme Candidapepsin-1", Journal of Applied Pharmaceutical Science, 2019

Publication

1 %

8

Rohit Patel, Jignesh Prajapati, Priyashi Rao, Rakesh M. Rawal, Meenu Saraf, Dweipayan Goswami. "Repurposing the antibacterial drugs for inhibition of SARS-CoV2-PLpro using molecular docking, MD simulation and binding energy calculation", Molecular Diversity, 2021

Publication

1 %

9

rasayanjournal.co.in

Internet Source

1 %

10 Tanmay Sarkar, Kaushik Kumar Bharadwaj, Molla Salauddin, Siddhartha Pati, Runu Chakraborty. "Phytochemical Characterization, Antioxidant, Anti-inflammatory, Anti-diabetic properties, Molecular Docking, Pharmacokinetic Profiling, and Network Pharmacology Analysis of the Major Phytoconstituents of Raw and Differently Dried *Mangifera indica* (Himsagar cultivar): an In Vitro and In Silico Investigations", *Applied Biochemistry and Biotechnology*, 2021
Publication

11 livrepositary.liverpool.ac.uk
Internet Source <1 %

12 opus.bath.ac.uk
Internet Source <1 %

13 worldwidescience.org
Internet Source <1 %

14 Submitted to Universitas Sam Ratulangi
Student Paper <1 %

15 Submitted to University of Melbourne
Student Paper <1 %

16 Submitted to Prince Sultan University
Student Paper <1 %

Submitted to Kingston University

17	Student Paper	<1 %
18	Submitted to University of Newcastle upon Tyne Student Paper	<1 %
19	Submitted to University of Wollongong Student Paper	<1 %
20	www.growingscience.com Internet Source	<1 %
21	www.frontiersin.org Internet Source	<1 %
22	www.matec-conferences.org Internet Source	<1 %
23	Ana C. Mafud, Marcos P.N. Silva, Geandra B.L. Nunes, Milene A.R. de Oliveira et al. "Antiparasitic, structural, pharmacokinetic, and toxicological properties of riparin derivatives", Toxicology in Vitro, 2018 Publication	<1 %
24	Silvana Giuliatti. "Chapter 3 Computer-Based Methods of Inhibitor Prediction", IntechOpen, 2013 Publication	<1 %
25	appliednetsci.springeropen.com Internet Source	<1 %

- 26 pdfs.semanticscholar.org
Internet Source <1 %
-
- 27 "Abstracts from 8th International ISSX Meeting", Drug Metabolism Reviews, 2010
Publication <1 %
-
- 28 journals.udsm.ac.tz
Internet Source <1 %
-
- 29 lifeanddiseases.blogspot.com
Internet Source <1 %
-
- 30 www.aai.aero
Internet Source <1 %
-
- 31 Adinda Adelia Wulandari, Achmad Aziz Choiri, Fitria, Tri Widiandani. " Thymoquinone and its derivatives against breast cancer with HER2 positive: studies of ADMET, docking and QSPR ", Journal of Basic and Clinical Physiology and Pharmacology, 2021
Publication <1 %
-
- 32 Joana Figueiredo, João L. Serrano, Mafalda Soares, Susana Ferreira, Fernanda C. Domingues, Paulo Almeida, Samuel Silvestre. "5-Hydrazinylethylidenepyrimidines effective against multidrug-resistant Acinetobacter baumannii: Synthesis and in vitro biological evaluation of antibacterial, radical scavenging <1 %

and cytotoxic activities", European Journal of Pharmaceutical Sciences, 2019

Publication

33

Mark A. Carfagna, Jesse Anderson, Christopher Eley, Tamio Fukushima et al. "Leveraging the Value of CDISC SEND Data Sets for Cross-Study Analysis: Incidence of Microscopic Findings in Control Animals", Chemical Research in Toxicology, 2020

Publication

<1 %

34

Muhammad Tukur Ibrahim, Adamu Uzairu, Gideon Adamu Shallangwa, Sani Uba. "MOLECULAR DOCKING INVESTIGATION AND PHARMACOKINETIC PROPERTIES PREDICTION OF SOME ANILINOPYRIMIDINES ANALOGUES AS EGFR T790M TYROSINE KINASE INHIBITORS", Egyptian Journal of Basic and Applied Sciences, 2021

Publication

<1 %

35

R. Vijayaraj, N. Sri Kumaran, K. Altaff, S. Ramadevi, A. Sherlin Rosita. " Pharmacokinetics and Molecular Docking of Novel Bioactive Compound (11-Methoxy-2-Methyltridecane-4-OI) for Inhibiting Carbohydrates Hydrolyzing Enzyme ", Journal of Biologically Active Products from Nature, 2020

Publication

<1 %

36

japsonline.com

Internet Source

<1 %

37

openaccess.uoc.edu

Internet Source

<1 %

38

Teresa Maria Creanza, Pietro Delre, Nicola Ancona, Giovanni Lentini, Michele Saviano, Giuseppe Felice Mangiatordi. "Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study", *Journal of Chemical Information and Modeling*, 2021

Publication

<1 %

39

W Haverkamp, L Eckardt, J Matz, K Frederiksen. "Sertindole: cardiac electrophysiological profile", *International Journal of Psychiatry in Clinical Practice*, 2009

Publication

<1 %

40

Ceres Fernandez-Rozadilla, Ana Rita Simões, Matilde E. Leonart, Amancio Carnero, Ángel Carracedo. "Tumor Profiling at the Service of Cancer Therapy", *Frontiers in Oncology*, 2021

Publication

<1 %

41

Heinz Bönisch. "Chapter 516 Substrates and Inhibitors of Organic Cation Transporters (OCTs) and Plasma Membrane Monoamine Transporter (PMAT) and Therapeutic Implications", Springer Science and Business Media LLC, 2021

Publication

<1 %

42

Mark A. Ator, John P. Mallamo, Michael Williams. "Overview of Drug Discovery and Development", Current Protocols in Pharmacology, 2006

Publication

<1 %

43

docplayer.net

Internet Source

<1 %

Exclude quotes On

Exclude matches Off

Exclude bibliography On